ArticleACS applied materials & interfaces2026
Injectable, Conductive, Multifunctional Hydrogels with Sustained Luteolin Release for Promoting Myocardial Infarction Repair.
Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) triggers a pathological cascade involving inflammation, oxidative stress, and electrophysiological dysfunction, collectively leading to adverse cardiac remodeling. To address these interconnected pathological challenges, we developed an injectable conductive hydrogel (FLCM). Constructed from a thermo-/photo-cross-linkable Pluronic F127 diacrylate matrix functionalized with luteolin, recombinant human collagen type I, and MXene nanosheets, FLCM exhibits excellent injectability, electrical conductivity, mechanical robustness, cell affinity, and sustained drug release capability. In a rat MI model, FLCM implantation effectively attenuated the inflammatory response by reducing pro-inflammatory cytokines (tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)) while promoting M2 macrophage polarization. Concurrently, it alleviated oxidative stress, preserved connexin 43 expression to enhance myocardial electrical coupling, and significantly lowered the incidence of ventricular arrhythmias. Through these synergistic actions, FLCM improved the infarct microenvironment, thereby suppressing excessive fibrosis, mitigating adverse cardiac remodeling, and restoring left ventricular function. Integrated transcriptomic profiling and protein-level validation revealed that FLCM synchronously modulated extracellular matrix reorganization and coordinated the regulation of the PI3K-Akt and NF-κB signaling pathways, while simultaneously activating the Nrf2/HO-1 antioxidant defense system. Therefore, this study presents an integrated hydrogel system that simultaneously targets multiple post-MI pathological processes, offering a translatable strategy for comprehensive cardiac repair and functional recovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.